Misguided Policies Undermining Pharmacy Benefits Would Dramatically Increase Federal Spending Pharmacy benefit companies are working every day to secure savings for patients, families, and taxpayers. They pass the savings, or rebates, negotiated from big drug companies directly to the health
In case you missed it, PCMA President and CEO JC Scott joined Prime Therapeutics’ webinar Beyond the Script: PBM Hot Topics in D.C. to discuss how pharmacy benefit companies innovate and deliver value for patients. The panel was moderated by Mostafa
A recent blog (“Payers and PBMs Profit from Obscure Pharmacy Fees, While Seniors See No Relief in Prescription Costs”) suggests performance-based price concessions are retained by PBMs, restrict the growth of independent pharmacies, and inflate Medicare Part D enrollee’s out-of-pocket costs—unfounded
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) issued the following statement on the final Contract Year 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Programs rule: “PCMA applauds CMS for delaying the
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) issued the following statement on today’s vote in the Senate Finance Committee to advance legislation impacting the Medicare Part D program and pharmacy benefit companies, or PBMs, that threatens to undermine
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) issued the following statement on today’s vote by the Federal Trade Commission (FTC): “We agree with the Federal Trade Commission’s acknowledgement that market dynamics for pharmacy benefit companies have changed over
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) supports the Centers for Medicare and Medicaid Services’ (CMS) proposal to promote the use of biosimilars in Medicare Part D. Pharmacy benefit companies, or PBMs, have long supported the development of
In a new web video, Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott discusses the critical role and value of pharmacy benefit companies, the root cause of high prescription drug prices, and how solutions to boost competition, especially
While Big Pharma pushes misguided policies targeting pharmacy benefits as part of a blame game designed to keep prescription drug prices high, former Members of Congress are reminding current lawmakers that they’ve seen this movie before. Congress has considered similar
©2024 PCMA. All Rights Reserved.
